Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Journal of Molecular Medicine · 2024-04 · 102 (4) · 479-493
DOI: 10.1007/s00109-024-02431-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 23.02.2024. Verfasst von Rafaela Nasser Veiga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Cytogenetics and Oncogenetics, Postgraduate Program in Genetics. Department of Genetics, Universidade Federal Do Paraná, Rua Coro…. Hauptthemen laut MEDLINE: Neoplasms, Erythropoietin, Receptor, EphA2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 179 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its noncanonical signaling pathway. Throughout cancer treatment, the emergence of drug-resistant tumor cells is relatively common. Since the early 2000s, researchers have focused on understanding the role of EphA2 in promoting drug resistance in different types of cancer, as well as finding efficient and secure EphA2 inhibitors. In this review, the current knowledge regarding induced resistance by EphA2 in cancer treatment is summarized, and the types of cancer that lead to the most cancer-related deaths are highlighted. Some EphA2 inhibitors were also investigated. Regardless of whether the cancer treatment has reached a drug-resistance stage in EphA2-overexpressing tumors, once EphA2 is involved in cancer progression and aggressiveness, targeting EphA2 is a promising therapeutic strategy, especially in combination with other target-drugs for synergistic effect. For that reason, monoclonal antibodies against EphA2 and inhibitors of this receptor should be investigated for efficacy and drug toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Human Cytogenetics and Oncogenetics, Postgraduate Program in Genetics. Department of Genetics, Universidade Federal Do Paraná, Rua Coronel Francisco Heráclito Dos Santos, 100, Jardim das AméricasCuritiba,…
ORCID-Profile: Daniela Fiori Gradia
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Veiga, R. N., de Azevedo, A. L. K., de Oliveira, J. C., & Gradia, D. F. (2024). Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer. Journal of Molecular Medicine, 102(4), 479-493. https://doi.org/10.1007/s00109-024-02431-x
Vancouver
Veiga RN, de Azevedo ALK, de Oliveira JC, Gradia DF. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer. Journal of Molecular Medicine. 2024;102(4):479-493. doi:10.1007/s00109-024-02431-x
BibTeX
@article{Veiga2024,
author = {Veiga, Rafaela Nasser and de Azevedo, Alexandre Luiz Korte and de Oliveira, Jaqueline Carvalho and Gradia, Daniela Fiori},
title = {Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer},
journal = {Journal of Molecular Medicine},
year = {2024},
volume = {102},
number = {4},
pages = {479--493},
doi = {10.1007/s00109-024-02431-x}
}
EUVIMED